MYNZ — Mainz Biomed NV Income Statement
0.000.00%
- $7.64m
- $6.96m
- $0.90m
Annual income statement for Mainz Biomed NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.281 | 0.494 | 0.577 | 0.53 | 0.895 |
Cost of Revenue | |||||
Gross Profit | -0.061 | 0.123 | 0.178 | 0.182 | 0.51 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.2 | 1.16 | 12.3 | 26.9 | 27.5 |
Operating Profit | -0.922 | -0.665 | -11.7 | -26.4 | -26.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.957 | -0.587 | -11.7 | -26.4 | -26.3 |
Net Income After Taxes | -0.957 | -0.587 | -11.7 | -26.4 | -26.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.957 | -0.587 | -11.7 | -26.4 | -26.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.957 | -0.587 | -11.7 | -26.4 | -26.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.071 | -0.044 | -0.693 | -1.87 | -1.62 |
Dividends per Share |